⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ARQT News
Arcutis Biotherapeutics, Inc. Common Stock
Arcutis Begins Enrolling Phase 1a/1b Study Evaluating ARQ-234, a CD200R Agonist, in Healthy Volunteers and Adults With Atopic Dermatitis
globenewswire.com
ARQT
Latigo Biotherapeutics Appoints Neha Krishnamohan as Chief Financial Officer and Chief Business Officer
businesswire.com
ARTV
XOMA
ARQT
Arcutis Management to Present at TD Cowen’s 46th Annual Health Care Conference
globenewswire.com
ARQT
Form 8-K
sec.gov
ARQT
Arcutis Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
globenewswire.com
ARQT
Professional Golfer Max Homa Joins Arcutis’ Free to Be Me Campaign, Urging Individuals with Seborrheic Dermatitis to Tee Up a Conversation with Their Healthcare Provider About Long-Term Treatments
globenewswire.com
ARQT
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
ARQT
Arcutis Announces Positive Topline Results for INTEGUMENT-INFANT Phase 2 Trial of ZORYVE® (roflumilast) Cream 0.05% in Infants with Mild to Moderate Atopic Dermatitis
globenewswire.com
ARQT
Arcutis Biotherapeutics, Inc. Announces Termination of Promotion Agreement with Kowa
globenewswire.com
ARQT
Arcutis to Report Fourth Quarter and Full Year 2025 Financial Results and Present at Upcoming Investor Conference
globenewswire.com
ARQT